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For many years adjuvant chemotherapy has been a standard treatment after complete
resection in malignancies such as breast and colon but only recently has its use become
standard in early stage non-small cell lung cancer (NSCLC). Although surgery is regarded
as the best possible treatment for early stage NSCLC, only 20–25% of patients have
resectable disease at presentation. Despite optimal surgical treatment, 5-year survival
rates for NSCLC remain 50–60% for stage IB, 40–50% for stage II, and 20–30% for stage
III (Kohler et al., 2011; Siegel et al., 2011). Adjuvant chemotherapy provides additional sur-
vival beneﬁt in resected NSCLC but questions remain as to how to select patients for
therapy and which regimen is best. Other than work with tegafur/uracil in Japan, the posi-
tive adjuvant trials have all utilized a cisplatin backbone, but the drug(s) to pair with cisplatin
are a matter of debate and will be discussed further in this manuscript.
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ADJUVANT CHEMOTHERAPY EMERGES FOR NSCLC
The adoption of adjuvant chemotherapy for patients with early
stage non-small cell lung cancer (NSCLC) is validated by three
meta-analyses – the 1995 NSCLC Collaborative Group, the Med-
ical Research Council (MRC), and the lung adjuvant cisplatin
evaluation (LACE). The ﬁrst large meta-analysis, the 1995 NSCLC
Collaborative Group demonstrated a trend toward overall survival
beneﬁt in eight cisplatin-based adjuvant trials (Non-Small Cell
Lung Cancer Collaborative Group, 1995). These results led to sub-
sequent larger adjuvant trials utilizing cisplatin-based chemother-
apywhichwere pooled in two recent largemeta-analyses, theMRC
and the LACE, both of which demonstrated a 5-year overall sur-
vival beneﬁt (HR 0.87; 95% CI 0.81–0.93; p< 0.000001; HR 0.89;
95% CI 0.82–0.96; p = 0.004, respectively; Stewart et al., 2007;
Pignon et al., 2008).
Five of the largest adjuvant trials to date were included in
LACE; two exclusively examined cisplatin–vinorelbine combina-
tions [National Cancer Institute of Canada (NCIC) JBR.10 and
Adjuvant Navelbine International Trialist Association (ANITA)]
while the other three allowed investigator-choice of cisplatin-based
regimens [big lung trial (BLT), International Trialist Associa-
tion Trial (IALT), and Adjuvant Lung Project Italy (ALPI)]. The
adjuvant trial showing the most striking beneﬁt, NCIC JBR.10,
included 482 patients with completely resected IB or II NSCLC
randomly assigned to observation or four cycles of weekly cis-
platin 50mg/m2 days 1, 8 plus vinorelbine 25mg/m2 days 1, 8,
15, 22 on a 28-day regimen (Winton et al., 2005). The ANITA
trial evaluated adjuvant treatment for 840 patients with resected
stage IB–IIIA NSCLC using cisplatin 100mg/m2 day 1 (4 doses)
plus vinorelbine at 30mg/m2 days 1, 8, 15, and 22 (16 doses) for
four cycles versus observation (Douillard et al., 2006). Both tri-
als demonstrated overall survival beneﬁt (HR 0.69, p = 0.004; HR
0.80, p = 0.017, respectively) and the survival advantage did not
diminish over time – 8.4% at 7 years follow-up.
The BLT, IALT, andALPI trials evaluated an investigator-chosen
cisplatin-based regimen. The negative BLT utilized 3-week reg-
imens with cisplatin/vindesine, mitomycin/ifosfamide/cisplatin,
mitomycin/vinblastine/cisplatin, or vinorelbine/cisplatin (Waller
et al., 2004). IALT, which showed overall survival beneﬁt at 5 years
(HR 0.86, p 0.03), but not at 7 years (HR 0.91, 95% CI 0.81–1.02),
enrolled 1867 patients and randomly assigned them to observation
or to three or four cycles of one of the four following regimens: cis-
platin plus etoposide, or a vinca alkaloid (vindesine, vinorelbine,
or vinblastine; IALT, 2004). Finally, the negative ALPI trial utilized
a regimen of three cycles of adjuvant cisplatin, mitomycin, and
vindesine, dosed every 3weeks (Scagliotti et al., 2003). Although
only three trials (ANITA, IALT, JBR.10) independently demon-
strated signiﬁcant survival beneﬁt ranging from 4 to 15% (HR
0.69–0.89), when pooled in LACE, cisplatin-based adjuvant ther-
apy improved 5-year survival ranging from 4 to 5.3% (HR= 0.89;
95% CI 0.82–0.96; p = 0.004). Owing to these encouraging results,
MRC and LACE reafﬁrmed the beneﬁt of adjuvant chemotherapy
for stage II and IIIA but left questions regarding therapy for those
with stage I disease. Many hypotheses have emerged about the
differential survival seen in the trials such as inclusion of various
stages, and differences in utilization of radiation therapy, but one
of the most striking variances in the trials of course is the addi-
tional chemotherapy paired with cisplatin. It is possible that the
additional agent(s) play a critical role in the amount of beneﬁt
provided by adjuvant chemotherapy.
THE CISPLATIN VERSUS CARBOPLATIN DEBATE
Cisplatin combinations are currently recommended as the back-
bone for adjuvant therapy given that all three positive trials after
1995 used a cisplatin-based regimen (two with vinorelbine; IALT,
2004; Winton et al., 2005; Douillard et al., 2006). Treatment with
cisplatin, though, is associated with a number of serious and
unpleasant side effects which, along with data demonstrating a
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role of carboplatin in metastatic settings, created the landscape
for competition between cisplatin and carboplatin. The only large
meta-analysis directly evaluating the two agents, albeit in advanced
stage disease, the cisplatin versus carboplatin (CisCa) trial, pro-
vides evidence of a trend toward superiority of cisplatin over car-
boplatin (Ardizonni et al., 2007). CisCa demonstrated improved
response rates with cisplatin therapy (30%) compared with car-
boplatin (24%) in 2968 patients (OR of 1.37; 95% CI 1.16–1.62;
p< 0.001). Subgroup analysis of patients with non-squamous
tumors and those treatedwith third-generation chemotherapy fur-
ther revealed that carboplatin-based chemotherapy was associated
with a statistically signiﬁcant increase in mortality (HR= 1.12;
95%CI 1.01–1.23 andHR= 1.11; 95%CI 1.01–1.21, respectively).
Though these results will need to be updated with the recently
presented BTOG2Phase III randomized trial which compared car-
boplatin/gemcitabine to two different cisplatin/gemcitabine regi-
mens and demonstrated equivalency of the carboplatin and cis-
platin (80mg/m2) arms, the majority of trials have still shown cis-
platin superiority in the metastatic setting (Ferry et al., 2011). Our
only data in early stage disease with carboplatin comes from the
negative CALGB9633 trial which utilized carboplatin/paclitaxel
for resected stage IB NSCLC (Strauss et al., 2008). Though this
study failed to show a survival advantage in the population with
the carboplatin regimen, the superiority of cisplatin may not be
the only explanation given the small sample size and the exclu-
sive inclusion of only stage IB. Based on the evidence to date,
currentNational ComprehensiveCancerNetwork (NCCN) guide-
lines, an organization comprised of an alliance of professionals
from 21 of the world’s leading cancer centers, recommend adju-
vant chemotherapy using a cisplatin-based regimen (Ettinger et al.,
2010). Therefore as there are no further studies planned to eval-
uate this research question of carboplatin versus cisplatin, unless
medically contraindicated, cisplatin is the platinum of choice in
the adjuvant setting.
IS THERE AN OPTIMAL REGIMEN?
There are little data regarding what the best cisplatin-based reg-
imen may be and though data is limited, many options are
recommended by organizations such as the NCCN. Currently,
the NCCN guidelines recommend combination cisplatin-based
therapy with previously studied third-generation agents vinorel-
bine, vincristine, etoposide, but also suggest combinations with
the newer agents gemcitabine, docetaxel, or pemetrexed which
have not yet been studied extensively in the adjuvant setting.
Pooled data from the LACE meta-analysis demonstrate a mar-
ginal trend toward survival using cisplatin/vinorelbine compared
with other cisplatin combinations (p = 0.04). Of the ﬁve tri-
als in LACE, the regimen with the most positive outcomes was
cisplatin/vinorelbine (ANITA and JBR.10). One reason for this
outcome may have more to do with delivery of the entire regimen
and not necessarily due the vinorelbine itself. Eighty-six percent of
the patientswho received cisplatin–vinorelbine regimenswere able
to receive a higher cisplatin dosing (>300mg/m2) compared with
other regimens. It is possible that this dose intensity of cisplatin
accounts for the differential beneﬁt in the vinorelbine containing
regimens. Currently, there are many modern drugs which have
yet to be studied in the adjuvant setting. Our only deﬁnitive data,
though, exists in the metastatic setting.
In the metastatic setting, the choice of therapy is a platinum-
based doublet with third-generation agents such as paclitaxel,
docetaxel, gemcitabine, vinorelbine, irinotecan, or pemetrexed.
(Schiller et al., 2002; Baggstrom et al., 2007). Although the overall
differential beneﬁt from modifying chemotherapy in the metasta-
tic setting has been small, the head-to-head comparisons of reg-
imens of other doublets over cisplatin–vinorelbine are found in
several studies. For instance, in the metastatic setting, the TAX 326
study group found that cisplatin–vinorelbine had a less favorable
overall response and survival rate compared to cisplatin–docetaxel
(24.5 versus 31.56%, p = 0.029; Fossella et al., 2003). Direct
comparison of cisplatin–docetaxel versus cisplatin–gemcitabine
have shown equivalency (Schiller et al., 2002). Comparisons
of cisplatin–pemetrexed to cisplatin–gemcitabine demonstrate a
superiority of cisplatin–pemetrexed in terms of survival (12.6
versus 10.9months) as well as tolerability in patients with non-
squamous histology (Scagliotti et al., 2008). Therefore, extrap-
olating from these studies one could postulate that cisplatin–
pemetrexed is superior to cisplatin–gemcitabine in non-squamous
patients and both are equivalent to cisplatin–taxane regimens and
that all three combinations are superior to cisplatin–vinorelbine
in the metastatic setting. Of course this is merely a stated opin-
ion at this time, and further studies will be needed to conﬁrm
this hypothesis, but many including the authors are now comfort-
able using other platinum doublets besides cisplatin/vinorelbine
as adjuvant therapy.
This is illustrated by the use of other platinum doublets as
adjuvant therapy when allowed on clinical trial in the United
States. From preliminary data of the Eastern Cooperative Oncol-
ogy Group 1505 trial (which is currently underway to investigate
the value in the adjuvant setting of the anti-vascular endothelial
growth factor receptor monoclonal antibody bevacizumab) par-
ticipating oncologists (primarily in the United States) are choos-
ing widely from the combinations of treatment available on the
trial which include four different cisplatin-based regimens: cis-
platin with gemcitabine, docetaxel, vinorelbine, or pemetrexed.
Out of the ﬁrst 636 patients (of a planned 1500) enrolled in
the trial, 27% received cisplatin+ vinorelbine, 33% received cis-
platin+ docetaxel, 25% received cisplatin+ gemcitabine and 16%
received cisplatin+ pemetrexed (only for non-squamous histol-
ogy and added as an option after enrollment had already begun;
Wakelee et al., 2010).
Tolerability of regimens however must be interpreted carefully
in the adjuvant setting as was noted from the Memorial Sloan Ket-
tering Cancer Center Phase II tolerability study of cisplatin plus
docetaxel in the adjuvant setting in NSCLC. In this trial the side
effect proﬁle led to poor completion of treatment with 55% of
patients failing to complete three cycles secondary to fatigue, nau-
sea, neutropenic fevers, hypotension, and renal side effects (Azzoli
et al., 2007). Further studies are similarly investigating the reﬁne-
ment of chemotherapy and tolerability in the adjuvant setting.
Preliminary results from the randomized phase II trial on reﬁne-
ment of early stage NSCLC adjuvant chemotherapy with cisplatin
and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb;
TREAT) was presented by Kreuter et al. (2011). This trial demon-
strated the feasibility of use of cisplatin–pemetrexed and the safety
of treatment as well as the higher dose density of this regimen
compared with cisplatin–vinorelbine. Although the efﬁcacy of
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cisplatin–pemetrexed compared to cisplatin–vinorelbine is yet to
be ﬁnalized one of the limitations of this trial is that 45% of the
patients included in the study have squamous histology and 38%
have stage IB which may signiﬁcantly reduce the overall efﬁcacy
of cisplatin–pemetrexed. For now, whether data can be translated
from the metastatic setting to the adjuvant setting is unknown but
data suggests that it is reasonable to conclude that substituting
other cisplatin-based doublets for cisplatin–vinorelbine may be
considered.
ADJUVANT CHEMOTHERAPY IN THE ELDERLY
Adjuvant therapy in the elderly is also a research area of particular
importance given that the median age of diagnosis of NSCLC is
70 years of age. In general, elderly patients receive less adjuvant
therapy but studies to date demonstrate that elderly can enjoy a
survival beneﬁt with treatment without any differences in toxici-
ties, hospitalizations, or treatment-related death by age group. In
the JBR.10 trial, out of 155 patients aged 65 years and older, adju-
vant chemotherapy signiﬁcantly prolonged overall survival (HR
0.61; 95%CI 0.38–0.98; p = 0.04; JBR10). In LACEwhich included
JBR.10, pooled analysis of 414 (9%) patients age 70 years and
older also demonstrated a trend toward survival beneﬁt with adju-
vant chemotherapy (HR 0.90; 95% CI 0.70–1.16; p = 0.29; Fruh
et al., 2008). These ﬁndings have improved rates of chemother-
apy administration in the elderly at least in the United States
and Canada as demonstrated in two abstracts presented at the
American Society of Clinical Oncology (ASCO) Annual meeting
in 2011. A population based study from Ontario Canada demon-
strated that administration of adjuvant therapy in patients over
70 increased from 3 to 16% over the years of 2001–2006 with
an overall survival improvement from 47 to 50% (Cuffe et al.,
2011). Despite concerns of toxicity from chemotherapy, 70% of
elderly were treated with cisplatin versus 28% treated with car-
boplatin. Similarly, in the United States, SEER data from 1992
to 2005 demonstrate that 19% of patients greater than age 65
received chemotherapy in the adjuvant setting (Gu et al., 2011),
but the use of carboplatin was extensive. The evidence of beneﬁt
of adjuvant therapy for patients age 66–74 is clear and treat-
ment should be offered for those patients with good performance
status.
IMPROVING PATIENT SELECTION AND FUTURE DIRECTIONS
Although the beneﬁt of adjuvant therapy is undeniable, the
improvement is modest. The role of predictive markers is cru-
cial as they may help us better select patients most likely to
beneﬁt from adjuvant therapy. In the IALT trial, patients with exci-
sion of repair cross-complementation group 1 (ERCC1)-negative
tumors showed prolonged survival (HR 0.65; 95% CI 0.50–0.86;
p = 0.002) compared with observation, however this was not true
among patients with ERCC1 positive tumors (HR= 1.14; 95% CI
0.84–1.55; p = 0.40; Olaussen et al., 2006). A recent update pre-
sented at ESMO 2011 demonstrated a ﬁnal HR of 0.91 during the
8-years of median follow-up and an observed 20% more deaths
among ERCC1 positive tumors with an OS (HR of 1.20; 95% CI
0.91–1.59) among patients with ERCC1 positive tumors. Multi-
ple trials ongoing in the US and Europe are seeking to validate
these results prospectively including SWOG 0720 which evaluated
adjuvant therapy with cisplatin/gemcitabine for stage 1 (>2 cm)
tumors in patients with low tumor expression of ERCC1 and
RRM1.
The Tailored Post-surgical therapy in early stage NSCLC
(TASTE) trial, Spanish Customized Adjuvant Trial (SCAT), and
International Tailored chemotherapy adjuvant trial (ITACA) are
all phase III trials using four chemotherapy possibilities based
on expression levels of ERCC1 and markers such as epidermal
growth factor receptor (EGFR) mutations, thymidylate synthase
expression and others. Gene expression patterns are also under
investigation by multiple groups. The MAGRIT (MAGE-A3 as
Adjuvant,Non-Small Cell Lung Cancer Immunotherapy) trial will
evaluate the MAGE-A3 Antigen Speciﬁc Cancer Immunothera-
peutic in the adjuvant setting and will hopefully shed light on
vaccinations as an adjuvant therapy for this patient population.
Targeted pathways are also important and have shown added
beneﬁt for patients who express particular gene mutations. The
EGFR gene mutations are one. Negative results from the NCIC
CTG BR.19 trial which evaluated geﬁtinib in completely resected
stage IB–IIIA NSCLC (only 21% of whom had EGFR mutations)
have raised questions. The BR.19 trial randomized 503 patients to
geﬁtinib versus placebo but the protocol was amended in Janu-
ary 2003 to allow adjuvant chemotherapy. Additionally, the trial
was halted early due to the interim analysis of S0023 SWOG trial
which demonstrated maintenance geﬁtinib was associated with
worse survival than placebo after concurrent chemoradiation for
stage III NSCLC. The numbers therefore in the BR.19 trial were
smallmaking any interpretations speculative at best (Thatche et al.,
2005). The Randomized double-blinded trial in Adjuvant NSCLC
with Tarceva (RADIANT) trial is evaluating the role of EGFR-TKI
erlotinib in the adjuvant treatment of 945 patients with resected
Stage IB–IIIA NSCLC whose tumors have overexpression of EGFR
detected by immunohistochemistry or FISH. Patients may have
up to four cycles of chemotherapy after surgery and are random-
ized 2:1 to erlotinib or placebo for 2 years. Patients randomized to
erlotinib beganwithin 6months of surgery if adjuvant chemother-
apy was administered or within 3months of surgery in adjuvant
chemotherapy was not given. This trial has completed accrual
and full EGFR and other molecular analyses are being completed.
Activation of angiogenesis is also an area of study. Despite the
absence of impact of bevacizumab, a monoclonal antibody that
targets angiogenesis, in adjuvant colorectal cancer, it has been
demonstrated to signiﬁcantly improve outcomes for patients with
advanced NSCLC when combined with doublet chemotherapy as
ﬁrst-line therapy in both the ECOG 4599 andAvastin in Lung can-
cer (AVAiL) trial. Based on these positive results, the ECOG 1505
trial randomizes patients to four cycles of cisplatin-based doublet
chemotherapy alone orwith bevacizumab dosed at 15mg/kg every
3weeks.
CONCLUSION
Although a research question over a decade ago, adjuvant cisplatin-
based chemotherapy is now the standard of care for patients
with resected stage II and IIIA, and selected stage IB NSCLC.
This is based on the results of phase III trials such as the IALT,
JBR.10, and ANITA studies. Although the optimum therapy is
still under investigation, and the strongest data to date show a
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trend favoring cisplatin–vinorelbine, there are many other cis-
platin doublets from which oncologists are already choosing. Data
from the metastatic setting extrapolated to the adjuvant setting
suggest that choosing cisplatin–pemetrexed, cisplatin–docetaxel,
or cisplatin–gemcitabine as an alternative to cisplatin–vinorelbine
is reasonable. Studies are underway to examine these regimens
further in this setting, with a strong focus on utilization of bio-
markers to select the best drugs for each patient. These future
studies will hopefully lead the way toward better survival for
patients with resectable NSCLC.
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